Unichem Laboratories Limited
Unichem Laboratories Ltd is involved in pharmaceuticalsin Generics, APIs and Contract Manufacturing (CMO) areas.
What Unichem files
- Others56
- Important31
- Board Meeting10
- Updates7
- Credit Ratings2
- Results1
Unichem Laboratories has extended the exercise period for the first and second tranches of vested employee stock options under its 2018 scheme, pushing the deadline to March 31, 2027. All other terms of the grants remain unchanged.
Company is initiating the transfer of shares to IEPF for investors with unclaimed dividends over seven years. Shareholders should claim their unpaid dividends by the given deadline to avoid transfer. Shares can still be reclaimed from IEPF post-transfer.
Unichem Labs faces a ₹1.77 Cr penalty from the National Pharmaceutical Pricing Authority for alleged drug overcharging. The company believes there is no material financial or operational impact and is evaluating legal options.
Unichem received a demand for a Euro 19.48 million fine from the European Commission for a past competition law breach. Euro 16.69 million remains payable. An additional Euro 5.51 million interest liability will impact FY26 earnings. Legal options are being evaluated.
Unichem Lab informed exchanges about submitting its Registrar's report. The report details the handling of re-lodged requests for physical share transfers, an administrative update on shareholder services.